Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$32.96
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | TEVA Avg Daily Volume: 10,899,300
Last Update: 03/28/17 - 4:02 PM EDT
Volume: 0
YTD Performance: -9.08%
Open: $0.00
Previous Close: $32.96
52 Week Range: $31.90 - $58.16
Oustanding Shares: 1,014,990,306
Market Cap: 33,525,129,807
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 6 5 8
Moderate Buy 1 1 1 1
Hold 8 8 10 7
Moderate Sell 0 0 0 0
Strong Sell 1 1 0 0
Mean Rec. 2.40 2.31 2.31 1.94
Latest Dividend: 0.29
Latest Dividend Yield: 3.50%
Dividend Ex-Date: 02/28/17
Price Earnings Ratio: 6.43
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
6.43 471.90 30.30
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-8.27% -38.80% -33.35%
GROWTH 12 Mo 3 Yr CAGR
Revenue 11.50 0.10 0.03
Net Income -80.50 -0.80 -0.37
EPS -96.20 -0.90 -0.64
Earnings for TEVA:
EBITDA 6.18B
Revenue 21.90B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.08 $1.09 $4.71 $4.73
Number of Analysts 5 5 8 7
High Estimate $1.19 $1.20 $5.00 $5.33
Low Estimate $0.98 $0.94 $4.39 $4.34
Prior Year $1.18 $1.25 $5.06 $4.71
Growth Rate (Year over Year) -8.81% -12.64% -6.94% 0.39%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
These two large-cap drug giants should be core parts of any well-diversified portfolio.
Yes, he's unpredictable, but is that a reason to sell?
Two industries should largely be avoided under this administration: pharma and retail.
Bearish
Jan 31, 2017 | 7:02 AM EST
Shares of TEVA now seen reaching $38, according to Barclays. Estimates also cut, given generic Copaxone competition.

Three Health-Care Growth Plays Real Money Pro($)

Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
This pharma company is still making lots of money and its stock is too cheap to pass up.
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid…
Drug giants with money to spend and a friendlier regulatory environment should spur deals.

Biotech Poised for Rebound Real Money Pro($)

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.
If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.